- On November 19, the Mexican
Senate passed comprehensive adult-use cannabis legalization, moving
Mexico towards becoming one of the
few countries to legalize cannabis nationally
- On March 31, 2020, the Company
entered into an agreement with Tecnologico de Monterrey, the leading university in
Mexico, to educate physicians
across Latin America, in advance
of the impending regulations in Mexico
- To date, close to 550 LatAm physicians have obtained their
diploma accrediting completion of Khiron's medical education
program
- The Company plans to deploy its ZereniaTM medical cannabis
clinics and telehealth strategy in Mexico, building on the success of its
vertical integration strategy in Colombia
- Expanding the Zerenia clinic strategy will build on the
Company's Colombia knowledge and
proven distribution capabilities, with rapid telehealth service
adoption and over 5,600 medical cannabis scripts filled to
date
- Mexico represents one of the
largest potential markets for medical cannabis in the world and is
anticipated to reach $1.2bn USD by
2028 (Prohibition Partners).
- Company to release Q3 2020 financials and host webcast on
Tuesday, December 1st
TORONTO, Nov. 27, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, welcomes the passing of adult-use
cannabis legislation by the Mexican Senate, which moves the country
closer to a legalized cannabis market, and towards provision for
medical cannabis products. Khiron has had a presence in
Mexico since 2018 and has been
working with doctors and medical institutions to develop a deep
understanding of the market.
"We are pleased to see the Mexican legislative and executive
branches working together to bring medical cannabis closer to a
reality. At Khiron, our goal is to improve the quality of life of 1
million patients by 2024 and Mexico will play an important role in our
strategy. Because of this, we partnered with Tecnologico de
Monterrey to bring our medical
cannabis education platform to doctors working in clinics and
health centres across Mexico and
LatAm. The clinic model is one we understand well and in which we
have proven success. As medical cannabis regulations continue to
evolve, we plan to take advantage of our vertical integration model
by deploying our Zerenia medical cannabis clinic and telehealth
strategy in Mexico,"
comments Alvaro Torres, Khiron CEO and Director.
Webcast and Q&A
Khiron invites individual and
institutional investors, as well as advisors and analysts, to
attend a webcast and Q&A to discuss the Company's Q3 2020
financial statements and further activities.
DATE: Tuesday, December 1st,
2020
TIME: 10:00am EST/7:00am PST
PRESENTERS: Alvaro Torres,
CEO and Director, Joel Friedman,
CFO, and Chris Naprawa, Chairman
FORMAT: Live 30 minutes presentation and Q&A session
REGISTER LINK:
https://event.on24.com/wcc/r/2819768/9328DB919FFBB024F2CF5F4F5119285E
About Khiron Life Sciences Corp.
Khiron is a
vertically integrated medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the
leading cannabis company in Colombia and the first company licensed in
Colombia for the cultivation,
production, domestic distribution and sales, and international
export of both low and high THC medical cannabis products. The
Company has filled medical cannabis prescriptions in Peru and has a presence in Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-plans-to-launch-its-zerenia-medical-cannabis-clinic-strategy-in-mexico-applauds-mexican-senate-approval-of-legislation-for-cannabis-in-mexico-301181071.html
SOURCE Khiron Life Sciences Corp.